# ZMYM3

Source: https://onco.cc/targets/zmym3/  
OnCo record `zmym3` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ZMYM3 (Zinc finger MYM-type protein 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer, Head and neck squamous cell carcinoma and 4 more.

## Summary

Required for regulation of cell morphology and cytoskeletal organisation.

Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.78, genetic association 0.00, somatic mutation 0.79). IntOGen calls it a driver in 15 cohorts (6 activating, 9 loss-of-function), covering Invasive Breast Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Head and Neck Squamous Cell Carcinoma, Lung Adenocarcinoma, Medulloblastoma, Prostate Adenocarcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: zinc finger MYM-type containing 3; Zinc finger MYM-type protein 3; ZNF198L2; DXS6673E; KIAA0385; ZNF261
- Tags: cancer-genes-wave
- Symbol: ZMYM3
- Class: tumor-suppressor
- Biology: Required for regulation of cell morphology and cytoskeletal organisation. Location: Nucleus (UniProt). Locus Xq13.1 (HGNC).
- Where found: Prostate cancer: Open Targets association 0.57 with prostate cancer (MONDO_0008315); IntOGen driver in 7 cohorts (PRAD, PROSTATE); Breast cancer: IntOGen driver in 1 cohort (BRCA); Head and neck squamous cell carcinoma: IntOGen driver in 1 cohort (HNSC); Chronic lymphocytic leukaemia: IntOGen driver in 2 cohorts (CLLSLL); Medulloblastoma: IntOGen driver in 2 cohorts (MBL); Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUAD)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 6 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 9 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:13054: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13054
- UniProt Q14202: https://www.uniprot.org/uniprotkb/Q14202/entry
- NCBI Gene 9203: https://www.ncbi.nlm.nih.gov/gene/9203
- Ensembl ENSG00000147130: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147130

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Medulloblastoma](https://onco.cc/cancers/medulloblastoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Thymoma (WHO types A, AB, B1, B2 and B3)](https://onco.cc/cancers/thymoma/)

---
JSON: https://onco.cc/api/v1/entities/zmym3.json